In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eligo Bioscience SAS

www.eligo-bioscience.com

Latest From Eligo Bioscience SAS

Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash

Genocea shifts to preclinical neoantigen-based cancer vaccines rather than advance a Phase III-ready herpes program on its own and Mateon gives up on its lead drug as placebo outperforms. Also, Juno tops recent public company financings and new VC funds back early-stage firms.

StartUps and SMEs Financing

Venture Funding Deals, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.

BioPharmaceutical Medical Device

Mining The Microbiome: Are Gut Microbes The Next Big Source Of Drugs?

There is growing interest in the gut microbiome as a source of new therapies across a wide range of diseases. Although it is still an emerging field, pharmaceutical firms and other investors are engaging, with more expected to follow.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Eligo Bioscience SAS
  • Senior Management
  • Xavier Duportet, PhD, CEO
    David Bikard, PhD, CSO
  • Contact Info
  • Eligo Bioscience SAS
    29 rue du Faubourg Saint-Jacques
    Paris, 75014
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register